Giuseppe Curigliano (President)
Istituto Europeo di Oncologia
Via Ripamonti, 435
20141 Milano, ITALY
Biography
Giuseppe Curigliano, MD PhD, is Full Professor of Medical Oncology at the University of Milano and Chief of the Clinical Division of Early Drug Development at European Institute of Oncology, Milano, Italy. Dr. Curigliano is an expert in the field of advanced drug development in solid tumors, with specific interest on breast cancer. He contributed to the development of many anticancer treatments actually available as standard of care in the treatment of multiple solid tumors. Since 2001 he is tenure-track and full-time cancer specialist at European Institute of Oncology – one of the world’s leading cancer-research institutes and the premier Cancer Center in Italy, third in Europe and 12th globally. He serves as member of the Italian Higher Health Council. Dr. Curigliano served ESMO as Chair of the Clinical Practice Guidelines Committee from 2019 to 2023. He was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. Dr Curigliano in 2022 and 2023 was identified as Clarivate™ world’s most influential researchers. Dr Curigliano has contributed to over 670 peer-reviewed publications.
Most relevant papers
G. Curigliano
Tarantino P, Marra A, Gandini S, Minotti M, Pricolo P, Signorelli G, Criscitiello C, Locatelli M, Belli C, Bellomi M, Curigliano G.
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents.
Eur J Cancer. 2020 Nov;139:92-98. doi: 10.1016/j.ejca.2020.08.026. Epub 2020 Sep 24. PMID: 32979647
G. Curigliano
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†.
Ann Oncol. 2020 Sep 23:S0923-7534(20)42460-3. doi: 10.1016/j.annonc.2020.09.010. Online ahead of print. PMID: 32979513 Free PMC article.
G. Curigliano
Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS.
Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Clin Cancer Res. 2020 Oct 12:clincanres.2380.2020. doi: 10.1158/1078-0432.CCR-20-2380. Online ahead of print. PMID: 33046517 Free article.
G. Curigliano
Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G.
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.
NPJ Breast Cancer. 2020 Oct 16;6:54. doi: 10.1038/s41523-020-00197-2. eCollection 2020. PMID: 33088912 Free PMC article. Review
G. Curigliano
Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, Morganti S, Passerini R, Orecchia R, Curigliano G.
Seroconversion in patients with cancer and oncology healthcare workers infected by SARS-CoV-2.
Ann Oncol. 2020 Oct 21:S0923-7534(20)42965-5. doi: 10.1016/j.annonc.2020.10.473. Online ahead of print. PMID: 33098994 Free PMC article.
G. Curigliano
Tagliabue M, Maffini F, Fumagalli C, Gandini S, Lepanto D, Corso F, Cacciola S, Ranghiero A, Rappa A, Vacirca D, Cossu Rocca M, Alterio D, Guerini Rocco E, Cattaneo A, Chu F, Zorzi S, Curigliano G, Chiocca S, Barberis M, Viale G, Ansarin M.
A role for the immune system in advanced laryngeal cancer.
Sci Rep. 2020 Oct 27;10(1):18327. doi: 10.1038/s41598-020-73747-0. PMID: 33110100 Free PMC article.
G. Curigliano
Tarantino P, Prat A, Curigliano G.
New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
Breast Cancer Res Treat. 2020 Oct 30. doi: 10.1007/s10549-020-05982-y. Online ahead of print. PMID: 33128191
G. Curigliano
Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, Mula-Hussain L, Errihani H, Khattak A, De Guzman RB, Mathias C, Alkaiyat MOF, Jradi H, Rolfo C; International Research Network on COVID-19 Impact on Cancer Care.
Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study.
JCO Glob Oncol. 2020 Sep;6:1428-1438. doi: 10.1200/GO.20.00351. PMID: 32986516 Free PMC article.
G. Curigliano
El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S.
Repurposing anticancer drugs for the management of COVID-19.
Eur J Cancer. 2020 Sep 22;141:40-61. doi: 10.1016/j.ejca.2020.09.014. Online ahead of print. PMID: 33125946 Free PMC article. Review.
G. Curigliano
Jazieh AR, Chan SL, Curigliano G, Dickson N, Eaton V, Garcia-Foncillas J, Gilmore T, Horn L, Kerr DJ, Lee J, Mathias C, Nogueira-Rodrigues A, Pierce L, Rogado A, Schilsky RL, Soria JC, Warner JL, Yoshida K.
Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars.
JCO Glob Oncol. 2020 Sep;6:1461-1471. doi: 10.1200/GO.20.00423. PMID: 32997537 Free PMC article.
